Buformin
Based on 3 publication(s) in Google Scholar
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al).
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 692-13-7
- Fòrmula: C6H15N5
- Peso molecular:157.22
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Buformin
MoreVer todos los productos específicos de isoformas AMPK
More
Actividad biológica
Descripciòn
In Vitro
Buformin (0-10 mM; 5 days) inhibits SKBR3 and BT474 cells growth as a concentration-dependent manner, exhibits IC50 values of 246.7 μM and 98.6 μM for erbB-2-overexpressing SKBR3 and BT474 cells, respectively[1].Buformin (0-3 mM; 48 hours) increases the percentage of cells in G0/G1 phase and reduced the percentage of cells in S phase, especially in the SKBR3 cells[1].Buformin (0-3 mM; 24 hours) suppresses RTK activation, including erbB-2 and IGF1R signaling downstream, and Akt activation/phosphorylation is inhibited in both SKBR3 and BT474 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 μM, 1 μM, 3 μM, 10 μM, 30 μM, 100 μM, 300 μM, 1, 3, or 10 mM
-
Incubation Time:5 days
-
Result:Reduced cell viability in erbB-2-overexpressing breast cells.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0.5 mM; 1 mM; 3 mM
-
Incubation Time:48 hours
-
Result:Increased cells arresting in G0/G1 phase.
-
Cell Line:ErbB-2-overexpressing SKBR3 and BT474 cells
-
Concentration:0 mM, 0.1 mM, 0.3 mM, 1 mM, or 3 mM
-
Incubation Time:24 hours
-
Result:Decreased p-AMPK, p-p706S, p-ERK1/2 expression in a concentration-dependent manner.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female MMTV-erbB-2 transgenic mice[1]
-
Dosage:7.6 mmol/kg
-
Administration:Oral administation; 7 days
-
Result:Inhibited mammary syngeneic tumor growth in MMTV-erbB-2 transgenic mice.
Chemical Information
-
No. CAS 692-13-7
-
Peso molecular 157.22
-
Fòrmula C6H15N5
-
SMILES
NC(NC(NCCCC)=N)=N
-
Synonyms
1-Butylbiguanide
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Clin Sci
Buformin alleviates sepsis-induced acute lung injury via inhibiting NLRP3-mediated pyroptosis through an AMPK-dependent pathway. [Abstract]2022 Feb 25;136(4):273-289. PMID: 35132999 -
Mol Metab
Developmental metformin exposure does not rescue physiological impairments derived from early exposure to altered maternal metabolic state in offspring mice. [Abstract]2024 Jan:79:101860. PMID: 38142972 -
Pureza y Documentación
Referencias
[1]. Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res [Content Brief]
[2]. Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)